Form 4: RVMD General Counsel Plans Future Stock Sale for Tax

Revolution Medicines General Counsel Jeff Cislini filed a Form 4 detailing a future sale of 1,869 common shares on September 16, 2025, to cover tax obligations from RSU vesting.

Summary

• Jeff Cislini, General Counsel of Revolution Medicines, Inc. (RVMD), reported a planned transaction.
• The transaction involves the disposition of 1,869 shares of common stock.
• The sale is scheduled to occur on September 16, 2025, at a price of $45.8249 per share.
• This sale is being made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023.
• The purpose of the sale is to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following this transaction, Mr. Cislini will beneficially own 52,224 shares, which includes 43,910 restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider stock sale for tax purposes under a 10b5-1 plan. This type of transaction is generally neutral and does not indicate a change in company fundamentals or management's confidence.

Future Outlook

The filing indicates a pre-planned future transaction for tax purposes, reflecting a routine aspect of executive compensation and tax management rather than a change in future outlook for the company.

Industry Context

This insider transaction is a routine disclosure for publicly traded companies, common in the biotechnology and pharmaceutical sectors where executive compensation often includes equity awards like RSUs, necessitating planned sales for tax obligations.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for pre-scheduled stock sales to cover tax liabilities from RSU vesting is a standard practice among executives in publicly traded companies, aligning with corporate governance best practices to avoid accusations of trading on material non-public information.
• The reported transaction volume of 1,869 shares is relatively small for an executive at a company like Revolution Medicines, Inc., suggesting it is a routine tax-related sale rather than a significant divestment of holdings.

Stakeholder Impact

• Shareholders: The sale is a routine, pre-planned event for tax purposes and is unlikely to have a significant impact on shareholder sentiment or the company's stock price due to its non-discretionary nature and relatively small volume.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Revolution Medicines, RVMD, Jeff Cislini, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Restricted Stock Units, Tax Withholding